<DOC>
	<DOCNO>NCT01988012</DOCNO>
	<brief_summary>A multi-center , open-label single-arm study evaluate efficacy safety tocilizumab administer single , weekly injection adult rheumatoid arthritis . Combination therapy methotrexate non-biologic disease modify anti-rheumatic drug ( DMARDs ) permit .</brief_summary>
	<brief_title>A Study Efficacy Safety Tocilizumab Adults With Rheumatoid Arthritis .</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<criteria>Adults &gt; /= 18 year age Diagnosis active rheumatoid arthritis ( RA ) accord revise ( 1987 ) American College Rheumatology ( ACR ) criteria European League Against Rheumatism ( EULAR ) /ACR ( 2010 ) criterion Previously treat following : three nonbiologic DMARDs , treat biologic agent OR one biologic agent ( alone combination nonbiologic DMARDs ) , discontinue agent reason Oral corticosteroid ( &lt; /= 10 mg/day prednisone equivalent ) , nonsteroidal antiinflammatory drug ( NSAIDs ) nonbiologic DMARDs permit stable dose regimen &gt; /= 4 week prior Baseline Use effective contraception throughout study define protocol ; female patient childbearing potential must pregnant Presence serious , uncontrolled , clinically significant medical condition History diverticulitis , diverticulosis require antibiotic treatment , chronic ulcerative low gastrointestinal ( GI ) disease might predispose perforation Current history recurrent bacterial , viral , fungal , mycobacterial , infection Any infection require hospitalization treatment intravenous ( IV ) antibiotic within 4 week Screening oral antibiotic within 2 week Screening Clinically significant finding lab test and/or hepatitis B C , human immunodeficiency virus ( HIV ) screening Active tuberculosis ( TB ) require treatment within previous 3 year Evidence active malignant disease , malignancy diagnose within previous 10 year , breast cancer diagnose within previous 20 year History alcohol , drug , chemical abuse within 1 year prior Screening Neuropathies condition might interfere pain evaluation Major surgery ( include joint surgery ) within 8 week prior Screening plan major surgery within 6 month follow Baseline Rheumatic autoimmune disease RA , include systemic lupus erythematosus , mixed connective tissue disorder , scleroderma , polymyositis , significant systemic involvement secondary RA ( e.g. , vasculitis , pulmonary fibrosis Felty 's syndrome ) . Secondary Sj√∂gren 's syndrome RA permit Functional Class IV define ACR Classification Functional Status inRheumatoid Arthritis Diagnosis juvenile idiopathic arthritis juvenile RA , and/or RA age 16 Prior history current inflammatory joint disease RA Exposure tocilizumab ( either IV subcutaneous administration ) time prior Baseline Treatment investigational agent within 4 week ( five halflives investigational drug , whichever long ) Screening Previous treatment celldepleting therapy , include investigational agent approve therapy , alkylating agent chlorambucil , total lymphoid irradiation Treatment IV gamma globulin , plasmapheresis within 6 month Baseline Immunization live/attenuated vaccine within 4 week prior Baseline</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>